| Literature DB >> 29228789 |
Fatemeh Farzaei1, Mohammad Reza Morovati2, Fatemeh Farjadmand2, Mohammad Hosein Farzaei1,3.
Abstract
Diabetes mellitus is the most common endocrine disorder and a major cause of morbidity and mortality. Traditional medicines worldwide suggest a wide range of natural remedies for the prevention and treatment of chronic disorders, including diabetes mellitus. This mechanistic review aims to highlight the significance of medicinal plants traditionally used as dietary supplements in Persian medicine in adjunct with restricted conventional drugs for the prevention and treatment of diabetes mellitus. Mounting evidence suggests that these natural agents perform their protective and therapeutic effect on diabetes mellitus via several cellular mechanisms, including regeneration of pancreatic β cell, limitation of glycogen degradation and gluconeogenesis, anti-inflammatory, immunoregulatory, antiapoptosis, antioxidative stress, as well as modulation of intracellular signaling transduction pathways. In conclusion, traditional medicinal plants used in Persian medicine can be considered as dietary supplements with therapeutic potential for diabetes mellitus and maybe potential sources of new orally active agent(s).Entities:
Keywords: complementary and alternative medicine; diabetes mellitus; dietary supplement; herbal medicine; traditional Persian medicine
Mesh:
Substances:
Year: 2017 PMID: 29228789 PMCID: PMC5871259 DOI: 10.1177/2156587216686461
Source DB: PubMed Journal: J Evid Based Complementary Altern Med ISSN: 2156-5899
Medicinal Plants with Anti-Diabetes Activity used in Traditional Persian Medicine.[21] -24
| Scientific Names | Family | Medicinal Part | Name(s) in Persian Medicine Resources | Uses in Persian Medicine |
|---|---|---|---|---|
|
| Leguminosae | Gum and fruit | Samghe arabi (gum), Aghaghia (fruit) | Gastric tonic, respiratory disorders, diarrhea, peptic ulcer, inflammatory bowel disease, diabetes |
|
| Poaceae | Dried exudate on nodes | Tabashir | Gastric and liver tonic, peptic ulcer, dysentery, aphthous, diabetes |
|
| Burseraceae | Oleo-gum resin | Kondor | Improvement of memory function, gastric tonic, peptic ulcer, inflammatory bowel disease, diabetes |
|
| Umbelliferae | Shokaran | Hypnotic, diarrhea, diabetes | |
|
| Umbelliferae | Fruit | Kozboreh, Geshniz | Carminative, insomnia, inflammation, dermatitis, eczema, scabies, scrofula, infected wounds and injury, diabetes |
|
| Fabaceae | Root | Shirin bayan, Sus | Gastric tonic, gastritis, diabetes, pulmonary disease |
|
| Asteraceae | Seed | Kahoo, Khas | Diuretic, hypnotic, diabetes |
|
| Myrtaceae | Fruit | Murd, Aas | Antidepressant, diarrhea, polymenorrhea, bruise, diabetes |
|
| Oxalidaceae | Fruit | Hammaz, Torshe | Liver tonic, appetizer, peptic ulcer, inflammatory bowel disease, diabetes |
|
| Portulacaceae | Seed | Khorfe, Baghle-al-homgha | Gastric tonic, urinary tract infections, lithontropic, diabetes, peptic ulcer, diabetes |
|
| Punicaceae | Flower | Golnar | Gastric and liver tonic, liver disease, peptic ulcer, inflammatory bowel disease, diabetes |
|
| Rosaceae | Flower and fruit | Gole sorkh, Vard | Antidepressant, gastric tonic, peptic ulcer, wounds and injury, diabetes |
|
| Santalaceae | Wood | Sandal-e-Sefid | Antidepressant, inflammation, headache, diabetes |
|
| Vitaceae | Unripe fruit | Ghoureh | Wound healer, hematopoietic, peptic ulcer, diabetes |
In Vitro Studies of Medicinal Plants used for the Treatment of Diabetes in Traditional Persian Medicine.
| Plant | Part/Extraction | Result | Active Constituent | Reference |
|---|---|---|---|---|
|
| Dried exudate/methanol extract | α-Amylase enzyme and α-glucosidase inhibitory activity | — | 27 |
|
| Oleo-gum resin | ↓Rat lens and kidney and human recombinant polyol enzyme aldose reductase activity and its advanced glycation end-products, which resulted in ↓chronic diabetic complications | Boswellic acid | 31 |
|
| Fruit/aqueous extract | ↑Glucose uptake, ↑glucose oxidation and ↑glycogenesis in mice abdominal muscle and ↑insulin secretion in rat pancreatic β-cell | — | 33 |
|
| Seed/methanol extract | α-Amylase enzyme and α-glucosidase inhibitory activity | — | 27 |
|
| Aerial part/isolated compound from 80% methanol extract | α-Glucosidase enzyme inhibitory activity | Myrtucommulone D, myrtucommulone E, myrtucommulone C, and myrtucommulone B | 41 |
|
| Leaf/various extract | α-Amylase enzyme inhibitory activity, aqueous extract showed the highest action | — | 43 |
|
| Seed/methanol extract | α-Amylase enzyme and α-glucosidase inhibitory activity | — | 27 |
|
| Flower/methanolic extract | ↑mRNA and protein expression of PPAR-γ, ↑PPAR-γ-dependent mRNA expression and ↑lipoprotein lipase in human THP-1-differentiated macrophage cells | Gallic acid | 49 |
|
| Flower/methanolic extract | α-Glucosidase enzyme inhibitory activity | — | 50 |
|
| Flower/methanolic extract | Inhibitory activity on α-glucosidase, which was noncompetitive | — | 54 |
|
| Seed/procyanidin extract | ↑Glucose uptake dose-dependently in insulin-sensitive cell lines (L6E9 myotubes and 3T3-L1 adipocytes), and ↑stimulation of insulin pathway mediators, which indicate insulinomimetic activity of procyanidins | Procyanidins | 56 |
In Vivo Studies of Medicinal Plants Used for the Treatment of Diabetes in Traditional Persian Medicine.
| Plant | Part/Route of administration | Method | Animal | Result | Active Constituents | Reference |
|---|---|---|---|---|---|---|
|
| Fruit/oral administration of fruit powder suspension | Aloxan (150 mg/kg s.c.) induced type 1 diabetes | Albino rabbit | Acute hypoglycemic activity in normal rabbit but there was no hypoglycemic action on diabetic animals | — | 25 |
|
| Bark/polyphenols | High-fat diet induced type 2 diabetes | KKAy mice | ↓Body weight, ↓FBS, ↑GLUT4 in skeletal muscle tissue and ↓serum insulin which indicate ↑insulin sensitivity. Improvement of energy expenditure-related mediators: ↑expression PPARα, PPARδ, CPT1, ACO and UCP3; as well as ↑expression of adiponectin and ↓TNF-α in white adipose tissue. Moreover, it suppresses fatty acid synthesis and fat intake in the liver | Robinetinidol and fisetinidol | 26 |
|
| Dried exudate/oral administration of polyherbal formula | STZ (50 mg/kg i.p.) induced type 1 diabetes | Wistar rat | ↓FBS, ↑serum insulin, ↓HbA1c, ↓total cholesterol, ↓triglycerides, ↓glucose-6-phosphatase, ↓fructose-1-6-biphophatase and ↑HDL-cholesterol, as well as improvement of pancreatic tissue and Langerhans islets | — | 27 |
|
| Leaf/oral administration of ethanol extract and fractions | STZ (60 mg/kg i.p.) induced type 1 diabetes | Wistar rat | ↓FBS via improvement of antioxidant function: ↓LPO, ↑SOD, ↑CAT and ↓GSH in pancreatic tissue. Also regeneration of Langerhans islet and pancreas tissue near to normal, as well as improvement of hepatocyte cells and kidney glomeruli and tubules | β-Sitosterol glucoside and stigmasterol | 28 |
|
| Oleo-gum resin/i.p. | Multiple low-dose STZ (40 mg/kg STZ for 5 days) induced type 1 diabetes | BK+/+ wild type mouse | ↓Penetration of lymphocytes into pancreatic islets, ↓apoptosis of periinsular cells, ↓G-CSF, ↓GM-CSF, ↓proinflammatory cytokines including: IL-1A, IL-1B, IL-2, IL-6, IFN-γ, TNF-α in the blood, inhibition of atrophy of pancreatic islet tissue and also ↓FBS in diabetic group in comparison with control mice | 11-Keto-β-boswellic acid and | 30 |
|
| Oleo-gum resin/orally | Aloxan (120 mg/kg s.c.) induced type 1 diabetes | Albino rat | ↑Body weight, ↓FBS, ↑serum insulin, ↑liver glycogen and also ↓degenerative changes in the β cells of pancreas in comparison with control group | — | 29 |
|
| Fruit/i.p. administration of ethanol extract | STZ (70 mg/kg i.p.) induced type 1 diabetes | Wistar rat | ↓FBS, ↑number and activity of pancreatic β cells, ↑insulin release from β cells | — | 32 |
|
| Fruit/as supplement in diet and drinking water | STZ (200 mg/kg i.p.) induced type 1 diabetes | Heterozygous lean mouse | ↓FBS, which was comparable to normal group | — | 33 |
|
| Root/glycyrrhizic acid | High-fat diet induced type 2 diabetes | Sprague-Drawley rat | ↓Mean blood glucose, ↑insulin sensitivity, as well as ↓insulin level. ↑Expression of lipoprotein lipase in visceral and subcutaneous adipose tissues, kidney, heart, and abdominal muscle, ↓fatty acid, ↓total cholesterol, ↓LDL cholesterol and also ↓lipid deposition in tissues | Glycyrrhizic acid | 35 |
|
| Root/glycyrrhizin | STZ induced diabetes | Wistar rat | ↓FBS, ↑serum insulin level, ↑pancreatic islet cells, ↓HbA1c, ↓cholesterol, ↓triglyceride, improvement of pancreas and kidney tissues, also ↑antioxidant function: SOD, CAT, MDA, and fructosamine | Glycyrrhizin | 36 |
|
| Dried exudate/oral administration of polyherbal formula | STZ (50 mg/kg i.p.) induced type 1 diabetes | Wistar rat | ↓FBS, ↑serum insulin, ↓HbA1c, ↓total cholesterol, ↓triglycerides, ↓glucose-6-phosphatase, ↓fructose-1-6-biphophatase and ↑HDL-cholesterol. Improvement of pancreatic tissue and Langerhans islets | — | 27 |
|
| Leaf/oral administration of volatile oil | Alloxan (200 mg/kg i.v.) induced diabetes | New Zealand albino rabbit | ↓FBS, ↓triglyceride, ↑CAT, ↑SOD, ↓nitrite-nitrate and ↓MDA in hepatic tissue; but no significant effect on liver activity biomarker | — | 38 |
|
| —/i.p. | STZ (50 mg/kg i.p.) induced diabetes | Wistar rat | ↓FBS, ↓MDA, improve kidney function such as ↑kidney weigh, ↓urine volume, ↓renal MDA, ↓urinary protein excretion, ↑Creatinine clearance, ↑renal GPx and ↓BUN | Myricetin | 40 |
|
| Leaf/oral administration of 50% ethanol extract | STZ (150 mg/kg i.p.) induced type 1diabetes, administration of the extract before (1) and after (2) diabetes induction | Mouse | Inhibition of initial hyperglycaemia (1), ↓FBS significantly (2) | — | 39 |
|
| Whole herb/oral administration of aqueous extract | Alloxan (120 mg/kg, i.p.) induced diabetes | Swiss albino mice | ↓FBS, ↓triglyceride, ↓LDL, ↓cholesterol, ↑HDL-cholesterol. Also improvement of antioxidant function: ↑SOD, ↑CAT, ↑GPx, ↓LPO, ↑Vit E, ↑Vit C and ↓GSH. | — | 42 |
|
| Aerial part/oral administration of aqueous extract | Genetic induced type 2 diabetes | db/db mice | ↓FBS, ↑insulin secretion, improvement of diabetic endothelial dysfunction through ↓triglyceride, ↓LDL-cholesterol, ↑HDL-cholesterol, ↓systolic blood pressure and ↑endothelium relaxant responses (↓vascular tension); as well as suppressing diabetic vascular inflammation: ↓ICAM-1, ↓VCAM-1, ↓MMP-2 and ↓E-selectin in aortic tissue | — | 47 |
|
| Leaf/oral administration of ethanolic extract | STZ (50 mg/kg i.p.) induced type 1 diabetes | Sprague-Dawley rat | ↓FBS via ↑antioxidant enzyme: ↑SOD and ↑CAT, ↑GSH-R and ↓LPO in liver and kidney tissue | — | 48 |
|
| Flower/oral administration of aqueous extract | STZ (60 mg/kg i.p.) induced type 1 diabetes | Albino Wistar rat | ↓FBS, ↓triglycerides, ↓cholesterol, ↓LDL-cholesterol, ↓VLDL, ↓LPO, ↑HDL-cholesterol, improvement of antioxidant enzymes: ↑GPx, ↑GSH-R, ↑GST, ↑SOD, ↑CAT and ↓GSH | — | 51 |
|
| Flower/oral administration of methanolic extract | Zucker diabetic fatty rats (type 2 diabetes) | Zucker rat | No significant effect on FBS, improve glucose tolerance effect, as well as ↑insulin sensitivity via ↑PPAR-γ mRNA expression and ↑GLUT4 mRNA expression (the insulin-dependent isoform of GLUTs) | Gallic acid | 49 |
|
| Flower/oral administration of methanolic extract | Sucrose loading mice (in vivo α-glucosidase enzyme inhibitory test), glucose loading and normal mice | Mouse | ↓Blood glucose in sucrose loading mice, but no effect on blood glucose in glucose loading and normal mice | — | 50 |
|
| Flower/oral administration of methanolic extract | Maltose loaded normal and STZ (50 mg/kg i.p.) induced type 1 diabetes (in vivo α-glucosidase enzyme inhibitory test) | Wistar rat | Inhibition of hyperglycemia subsequent to high-dose maltose uptake in both normal and diabetic rats, which indicate α-glucosidase activity | — | 54 |
|
| Fruit/oral administration of ethanol extract and various fractions | STZ (55 mg/kg i.p.) induced type 1diabetes | Albino rats | ↓FBS with antioxidant function | — | 55 |
|
| Seed/oral administration of water-acetone extract | High-fat diet induced type 2 diabetes | C57BL/6J mouse | ↑Protective activity from nerve fiber against diabetic peripheral neuropathy | Oligomeric proanthocyanidins | 57 |
|
| Seed/oral administration of ethanol extract and its fractions | Genetic induced type 2 diabetes | db/db mice | Whole extract and the ethylacetate/ethanol fraction showed ↓FBS, ↓HbA1c, but no effect on mice body weight | — | 59 |
|
| Seed/oral administration of proanthocyanidin extract | STZ (55 mg/kg i.v.) induced type 2 diabetes | Wistar rat | ↓FBS, ↓advanced glycation end products, ↓HbA1c, improve kidney function: ↓BUN, ↓creatinine, ↓kidneys/body weight ratio, ↓glomerular hypertrophy, ↓interstitial fibrosis, and also suppression of various protein overexpression ie, ↓GSTM, ↓glutamate carboxypeptidase and ↓β-actin protein expression | Proanthocyanidin | 58 |
|
| Seed/oral administration of procyanidin extract | STZ (70 mg/kg i.p.) induced type 1 diabetes | Wistar rat | ↓Blood glucose level, which was strengthened in accompany with low dose of insulin | Procyanidins | 56 |
Abbreviations: FBS, fasting blood glucose; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte/macrophage colony-stimulating factor; IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; i.p., intraperitoneal; s.c., subcutaneous; iv., intravenous; CAT, catalase, SOD, superoxide dismutase; MDA, malondialdehyde; GPx, glutathione peroxidase; BUN, blood urea nitrogen; ICAM, intercellular cell adhesion molecule; VCAM, endothelial vascular cell adhesion molecule; MMP, matrix metalloproteinase; GSH, reduced glutathione; GSH-R, glutathione reductase; LPO, lipid peroxidation; HbA1c, glycosylated hemoglobin; GSTM, glutathione S-transferase mu; PPAR, peroxisome proliferator-activated receptor; CPT1, carnitine palmitoyl-transferase1; ACO, acyl CoA oxidase; UCP3, uncoupling protein3; GLUT, glucose transporters; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low density lipoprotein; GST, glutathione S-transferase.
Human Studies of Medicinal Plants used for the Treatment of Diabetes in Traditional Persian Medicine.
| Plant | Preparations | Study Design | Disease | No. of Patients | Treatment Duration | Result | Reference | |
|---|---|---|---|---|---|---|---|---|
| Treatment Group | Control Group | |||||||
|
| Fruit/powder | — | Quasi-experimental study | Type 2 diabetic patients | 50 | 6 weeks | ↓FBS, ↓total cholesterol, ↓triglyceride, and ↓LDL- cholesterol ( | 34 |
|
| Seed/powder | Randomized double-blind placebo-controlled clinical trial | Type 2 diabetic women | 16 | 8 weeks | ↑Glucagon like peptide-1 concentrations, but no significant effect on Glucagon-like peptide-1 receptor | 45 | |
|
| Seed/sachet | Metformin | Randomized double-blind controlled clinical trial | Type 2 diabetic patients | 30 | 8 weeks | ↓Serum triglycerides, ↓total cholesterol, ↓LDL-cholesterol, ↓total and direct bilirubin, ↓fasting and postprandial blood glucose, ↓insulin (improvement of insulin resistance), ↓body weight and BMI, ↑HDL-cholesterol, and ↓liver biomarkers, including ALT, AST, and GGT | 46 |
|
| Fruit/concentrated juice | — | Quasi-experimental study | Type 2 diabetic patients | 26 | 8 weeks | ↓Total cholesterol, ↓LDL-cholesterol, ↓LDL-cholesterol/HDL-cholesterol, ↓total cholesterol/HDL-cholesterol and no significant effect on serum triacylglycerol and HDL-cholesterol level | 52 |
|
| Fruit/polyphenol extract | — | Randomized double-blind placebo controlled clinical trial | First-degree relatives of type 2 diabetic patients | 38 | 9 weeks | ↑Hepatic insulin sensitivity index, ↓glucose infusion rate, ↓oxidative stress: systemic and muscle MDA and protein carbonylation and ↑mitochondrial respiration | 59 |
|
| Fruit/resveratrol | — | Randomized double-blind placebo controlled clinical trial | Type 2 diabetic patients | 19 | 4 weeks | ↓FBS, ↑insulin sensitivity index, ↓oxidative stress including ↑platelet Akt phosphorylation, ↑urinary ortho-tyrosine excretion, but no effect on β-cell function and serum insulin level were observed | 48 |
|
| Seed/ethanolic extract | — | Randomized double-blind placebo controlled clinical trial | Type 2 diabetic patients | 2 months | There was no significant effect on FBS, antioxidant parameters, including total antioxidant capacity, SOD, GPx, and MDA levels in comparison with placebo group | 61 | |
Abbreviations: ND, not determined; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALT, alanine transaminase; AST, aspartate transaminase; GGT, γ-glutamyl transaminase; BMI, body mass index; MDA, malondialdehyde; Akt, protein kinase B; SOD, superoxide dismutase; GPx, glutathione peroxidase; FBS, fasting blood glucose.